RA CAPITAL MANAGEMENT, L.P.
Q4 2022 13F-HR Holdings
Net value change ($000)
+243,173
(5.2%)
New positions
9
Sold out positions
21
Turnover %
16.3%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q3 2022
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| PCVX | 170,916 | 155.5% |
| DICE Therapeutics, Inc. | 108,049 | 102.3% |
| VOR | 107,019 | 241.8% |
| JBIO | 105,118 | 76.7% |
| VRNA | 103,258 | 167.0% |
| Inhibrx, Inc. | 94,959 | NEW |
| RNAM | 85,643 | 242.0% |
| 89bio, Inc. | 68,940 | 153.0% |
| ASND | 68,218 | 8.7% |
| WAVE LIFE SCIENCES LTD | 58,315 | 93.9% |
Top Reduces (Value $000, Stocks/ETFs)
| Forma Therapeutics Holdings, Inc. | -179,782 | -100.0% |
| BIIB | -102,757 | -41.0% |
| RLMD | -74,040 | -100.0% |
| Third Harmonic Bio, Inc. | -63,635 | -96.5% |
| CTKB | -60,348 | -30.6% |
| NS Wind Down Co., Inc. | -57,627 | -98.0% |
| NKTX | -55,963 | -54.5% |
| ENTA | -46,513 | -100.0% |
| ABOS | -45,239 | -46.2% |
| GERN | -39,204 | -55.6% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|